Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452056 · ClinicalTrials.gov registry record
COVID-19 SARS-CoV-2 RAST Study
A clinical trial of SARS CoV 2 Infection, sponsored by Columbia University.
- Completed
- Registry status
- 337
- Enrollment target
- 1
- Study location
NCT06452056: Completed study of SARS CoV 2 Infection, sponsored by Columbia University.
NCT06452056 is a study of SARS CoV 2 Infection that has completed, run by Columbia University. The registered enrollment target is 337 participants, below the 4,178-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06452056, a study of SARS CoV 2 Infection, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 337 participants
- Enrollment target
- 1
- Study location
Study Summary
The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device. The primary objectives of this study are to 1) Evaluate the clinical performance of COV-SCAN; 2.) Assess the usability of COV-SCAN and the paired app as an over-the-counter product to be used by lay persons in non- laboratory settings. The clinical performance and usability data will be submitted as part of an application for Emergency Use Authorization (EUA) to the FDA. 3) Assess acceptability and feasibility of the COV-SCAN test, paired app, and frequent testing regimen in demonstration projects in university and workforce settings.
Primary Outcome
Evaluate the clinical performance of COV-SCAN; Determine the accuracy of the COV-SCAN test compared to the RT-PCR test.
Conditions Studied
Interventions
- DEVICE Rapid Antigen Screening Test
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2022-12-30 |
What the finished NCT06452056 record still lists
NCT06452056 is an observational study that tracks outcomes without assigning an intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, below the 4,178-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (92% lower).
The record links to 1 condition, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 1 intervention - of which Rapid Antigen Screening Test is the first listed.
NCT06452056 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06452056 about?
NCT06452056 is a clinical study titled "COVID-19 SARS-CoV-2 RAST Study". The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device. The primary objectives of this study are to 1) Evaluate the clinical performance of COV-SCAN; 2.) Assess the usability of COV-SCAN and the paired app as an over-the-...
What is the current status of trial NCT06452056?
This trial is currently completed. The enrollment target is 337 participants. The study started on 2021-01-07. Estimated completion is 2022-12-30.
What conditions does trial NCT06452056 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection.
What interventions are being tested in trial NCT06452056?
The interventions under investigation include: Rapid Antigen Screening Test (DEVICE).
Who is sponsoring clinical trial NCT06452056?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452056 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06452056's enrollment target sits among peer trials
337 21st of 35 higher than 15 of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
-
COVID-19 Transmission and Morbidity in Malawi
RECRUITING
-
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI